News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

November 30, 2020 Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
November 19, 2020 Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
November 16, 2020 Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
November 13, 2020 Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
November 11, 2020 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 5, 2020 Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
November 2, 2020 Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
October 27, 2020 Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
October 19, 2020 Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
October 15, 2020 Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity